Last Updated : August 5, 2022
Details
Review Type: Rapid
Provisional Funding Algorithm |
|
|---|---|
| Draft Report Posted: | June 23, 2022 |
| Stakeholder Feedback Deadline: | June 30, 2022 |
| Final Report Posted: | August 5, 2022 |
Details
| Call for patient/clinician input open | 22-Jun-22 |
|---|---|
| Call for patient/clinician input closed | 22-Aug-22 |
| Clarification: - Patient input submission received from and the Canadian Cancer Society and the Canadian Cancer Survivor Network | |
| Submission received | 21-Jul-22 |
| Submission accepted | 24-Aug-22 |
| Review initiated | 25-Aug-22 |
| Draft Canada's Drug Agency review report(s) provided to sponsor for comment | 16-Nov-22 |
| Deadline for sponsors comments | 25-Nov-22 |
| Canada's Drug Agency review report(s) and responses to comments provided to sponsor | 22-Dec-22 |
| Expert committee meeting (initial) | 11-Jan-23 |
| Draft recommendation issued to sponsor | 24-Jan-23 |
| Draft recommendation posted for stakeholder feedback | 02-Feb-23 |
| End of feedback period | 16-Feb-23 |
| Final recommendation issued to sponsor and drug plans | 03-Mar-23 |
| Final recommendation posted | 22-Mar-23 |
| Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s) | 20-Mar-23 |
| Canada's Drug Agency review report(s) posted | 18-May-23 |
Last Updated : July 24, 2024
Details
| Call for patient/clinician input open | June 14, 2022 |
|---|---|
| Call for patient/clinician input closed | August 08, 2022 |
| Submission received | July 14, 2022 |
| Review initiated | July 29, 2022 |
| Draft Canada's Drug Agency review report(s) provided to sponsor for comment | October 21, 2022 |
| Deadline for sponsors comments | November 01, 2022 |
| Canada's Drug Agency review report(s) and responses to comments provided to sponsor | November 29, 2022 |
| Expert committee meeting (initial) | December 07, 2022 |
| Draft recommendation issued to sponsor | December 20, 2022 |
| Draft recommendation posted for stakeholder feedback | January 05, 2023 |
| End of feedback period | January 19, 2023 |
| Final recommendation issued to sponsor and drug plans | February 03, 2023 |
| Final recommendation posted | February 22, 2023 |
| Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s) | February 17, 2023 |
| Canada's Drug Agency review report(s) posted | April 27, 2023 |
Last Updated : May 1, 2023
Details
| Call for patient/clinician input open | June 08, 2022 |
|---|---|
| Call for patient/clinician input closed | July 29, 2022 |
| Clarification: - Patient input submission received from Canadian Arthritis Patient Alliance, Arthritis Society, Canadian Skin Patient Alliance, CreakyJoints, Arthritis Consumer Experts, The Kidney Foundation of Canada, Lupus Canada, and Lupis Ontario | |
| Submission received | July 07, 2022 |
| Submission accepted | July 22, 2022 |
| Review initiated | July 22, 2022 |
| Draft Canada's Drug Agency review report(s) provided to sponsor for comment | October 06, 2022 |
| Deadline for sponsors comments | October 18, 2022 |
| Canada's Drug Agency review report(s) and responses to comments provided to sponsor | November 11, 2022 |
| Expert committee meeting (initial) | November 23, 2022 |
| Draft recommendation issued to sponsor | December 05, 2022 |
| Draft recommendation posted for stakeholder feedback | December 15, 2022 |
| End of feedback period | January 06, 2023 |
| Final recommendation issued to sponsor and drug plans | January 19, 2023 |
| Final recommendation posted | |
| Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s) | February 03, 2023 |
| Canada's Drug Agency review report(s) posted | April 10, 2023 |
Last Updated : April 10, 2023
Details
| Call for patient/clinician input open | 06-Jun-22 |
|---|---|
| Call for patient/clinician input closed | 29-Jul-22 |
| Clarification: - Patient input submission received from the Canadian Cancer Society | |
| Call for industry input open | 06-Jun-22 |
| Call for industry input closed | 29-Jul-22 |
| Review initiated | 06-Jun-22 |
| Expert committee meeting (initial) | 29-Jun-23 |
| Draft recommendation posted for stakeholder feedback | 20-Jul-23 |
| End of feedback period | 03-Aug-23 |
| Final recommendation posted | 08-Sep-23 |
| Canada's Drug Agency review report(s) posted | 08-Sep-23 |
Last Updated : September 11, 2023
Details
| Call for patient/clinician input open | June 02, 2022 |
|---|---|
| Call for patient/clinician input closed | July 22, 2022 |
| Clarification: - Patient input submission received from Fighting Blindness Canada, The Canadian Council of the Blind, CNIB, Vision Loss Rehabilitation Canada, Diabetes Canada | |
| Submission received | June 30, 2022 |
| Submission accepted | July 15, 2022 |
| Review initiated | July 18, 2022 |
| Draft Canada's Drug Agency review report(s) provided to sponsor for comment | October 06, 2022 |
| Deadline for sponsors comments | October 18, 2022 |
| Canada's Drug Agency review report(s) and responses to comments provided to sponsor | November 11, 2022 |
| Expert committee meeting (initial) | November 23, 2022 |
| Draft recommendation issued to sponsor | December 07, 2022 |
| Draft recommendation posted for stakeholder feedback | December 15, 2022 |
| End of feedback period | January 06, 2023 |
| Final recommendation issued to sponsor and drug plans | January 18, 2023 |
| Final recommendation posted | February 08, 2023 |
| Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s) | February 02, 2023 |
| Canada's Drug Agency review report(s) posted | March 29, 2023 |
Last Updated : April 19, 2023
Details
| Call for patient/clinician input open | May 26, 2022 |
|---|---|
| Call for patient/clinician input closed | July 15, 2022 |
| Clarification: - Patient input submission received from Asthma Canada | |
| Submission received | June 28, 2022 |
| Submission accepted | July 13, 2022 |
| Review initiated | July 14, 2022 |
| Draft Canada's Drug Agency review report(s) provided to sponsor for comment | October 05, 2022 |
| Deadline for sponsors comments | October 17, 2022 |
| Canada's Drug Agency review report(s) and responses to comments provided to sponsor | November 11, 2022 |
| Expert committee meeting (initial) | November 23, 2022 |
| Draft recommendation issued to sponsor | December 07, 2022 |
| Draft recommendation posted for stakeholder feedback | December 15, 2022 |
| End of feedback period | January 06, 2023 |
| Final recommendation issued to sponsor and drug plans | January 20, 2023 |
| Final recommendation posted | February 08, 2023 |
| Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s) | February 06, 2023 |
| Canada's Drug Agency review report(s) posted | April 18, 2023 |
Last Updated : April 18, 2023
Details
| Call for patient/clinician input open | May 20, 2022 |
|---|---|
| Call for patient/clinician input closed | July 15, 2022 |
| Clarification: - Patient input submission received from Canadian Breast Cancer Network and Rethink Breast Cancer | |
| Submission received | June 20, 2022 |
| Submission accepted | July 05, 2022 |
| Review initiated | July 06, 2022 |
| Draft Canada's Drug Agency review report(s) provided to sponsor for comment | September 20, 2022 |
| Deadline for sponsors comments | September 29, 2022 |
| Canada's Drug Agency review report(s) and responses to comments provided to sponsor | October 28, 2022 |
| Expert committee meeting (initial) | November 09, 2022 |
| Draft recommendation issued to sponsor | November 22, 2022 |
| Draft recommendation posted for stakeholder feedback | December 01, 2022 |
| End of feedback period | December 15, 2022 |
| Final recommendation issued to sponsor and drug plans | January 06, 2023 |
| Final recommendation posted | January 24, 2023 |
| Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s) | January 20, 2023 |
| Canada's Drug Agency review report(s) posted | March 20, 2023 |
Last Updated : March 20, 2023
Details
| Call for patient/clinician input open | May 17, 2022 |
|---|---|
| Call for patient/clinician input closed | July 11, 2022 |
| Clarification: - Patient input submission received from Canadian Cancer Society and Canadian Cancer Survivor Network | |
| Submission received | June 16, 2022 |
| Submission accepted | June 30, 2022 |
| Review initiated | July 04, 2022 |
| Draft CADTH review report(s) provided to sponsor for comment | September 26, 2022 |
| Deadline for sponsors comments | October 05, 2022 |
| CADTH review report(s) and responses to comments provided to sponsor | October 28, 2022 |
| Expert committee meeting (initial) | November 09, 2022 |
| Draft recommendation issued to sponsor | November 23, 2022 |
| Draft recommendation posted for stakeholder feedback | December 01, 2022 |
| End of feedback period | December 15, 2022 |
| Final recommendation issued to sponsor and drug plans | January 05, 2023 |
| Final recommendation posted | January 23, 2023 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | January 19, 2023 |
| CADTH review report(s) posted | March 28, 2023 |
Last Updated : January 29, 2025
Details
| Call for patient/clinician input open | May 11, 2022 |
|---|---|
| Call for patient/clinician input closed | July 04, 2022 |
| Clarification: - Patient input submission received from Lymphoma Canada | |
| Submission received | June 09, 2022 |
| Submission accepted | June 23, 2022 |
| Review initiated | June 24, 2022 |
| Draft Canada's Drug Agency review report(s) provided to sponsor for comment | September 16, 2022 |
| Deadline for sponsors comments | September 27, 2022 |
| Canada's Drug Agency review report(s) and responses to comments provided to sponsor | October 28, 2022 |
| Expert committee meeting (initial) | November 09, 2022 |
| Draft recommendation issued to sponsor | December 20, 2022 |
| Draft recommendation posted for stakeholder feedback | January 05, 2023 |
| End of feedback period | January 19, 2023 |
| Final recommendation posted | February 22, 2023 |
| Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s) | February 17, 2023 |
| Canada's Drug Agency review report(s) posted | June 09, 2023 |
Last Updated : June 9, 2023